<DOC>
	<DOCNO>NCT02662569</DOCNO>
	<brief_summary>The primary hypothesis dose regimen SC evolocumab ( AMG 145 ) combination statin therapy well tolerate result great reduction LDL-C diabetic subject hyperlipidemia mixed dyslipidemia .</brief_summary>
	<brief_title>A Double-blind , Randomized Study Diabetic Subjects With Hyperlipidemia Mixed Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Males female type 2 diabetes ( receive pharmacologic treatment least 6 month longer ) stable diabetes therapy , Lipidlowering therapy must unchanged least 4 week , Subjects receive statin therapy screen must fast LDLC great equal 100 mg/dL , Subjects receive statin therapy screening must fast LDLC great equal 130 mg/dL . Exclusion criterion : NYHA III IV heart failure , Uncontrolled cardiac arrhythmia , Uncontrolled hypertension , Type 1 diabetes poorly control type 2 diabetes , Uncontrolled hypothyroidism hyperthyroidism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>